학술논문

Predicting Isocitrate Dehydrogenase Status in Non-Contrast-Enhanced Adult-Type Astrocytic Tumors Using Diffusion Tensor Imaging and 11 C-Methionine, 11 C-Choline, and 18 F-Fluorodeoxyglucose PET.
Document Type
Article
Source
Cancers. Apr2024, Vol. 16 Issue 8, p1543. 12p.
Subject
*BRAIN physiology
*PREOPERATIVE period
*GLIOMAS
*RADIOPHARMACEUTICALS
*PREDICTION models
*DEOXY sugars
*MAGNETIC resonance imaging
*POSITRON emission tomography
*METHIONINE
*DESCRIPTIVE statistics
*CHOLINE
*THALAMUS
*OXIDOREDUCTASES
*GENETIC mutation
*BRAIN tumors
*OVERALL survival
Language
ISSN
2072-6694
Abstract
Simple Summary: Predicting the isocitrate dehydrogenase (IDH) mutation status is difficult in preoperative non-enhanced astrocytic tumors. We aimed to differentiate IDH status using preoperative MRI and PET. We found that patients with IDH-mutant (mut) astrocytomas were significantly younger than those with IDH-wildtype (wt) glioblastomas. The tumor location, fractional anisotropy, and mean diffusivity on MRI were significantly related to the IDH mutation status. PET showed significantly higher uptakes for 11C-methionine, 11C-choline, and 18F-fluorodeoxyglucose in IDH-wt than in IDH-mut tumors. Together, these findings reflect the higher malignancy of IDH-wt than of IDH-mut tumors. Composite diagnosis using age, MRI, and PET findings resulted in high accuracy for predicting IDH status. Thus, approaches based on biological tumor behavior in early-stage gliomas are helpful for guiding preoperative treatment decisions. We aimed to differentiate the isocitrate dehydrogenase (IDH) status among non-enhanced astrocytic tumors using preoperative MRI and PET. We analyzed 82 patients with non-contrast-enhanced, diffuse, supratentorial astrocytic tumors (IDH mutant [IDH-mut], 55 patients; IDH-wildtype [IDH-wt], 27 patients) who underwent MRI and PET between May 2012 and December 2022. We calculated the fractional anisotropy (FA) and mean diffusivity (MD) values using diffusion tensor imaging. We evaluated the tumor/normal brain uptake (T/N) ratios using 11C-methionine, 11C-choline, and 18F-fluorodeoxyglucose PET; extracted the parameters with significant differences in distinguishing the IDH status; and verified their diagnostic accuracy. Patients with astrocytomas were significantly younger than those with glioblastomas. The following MRI findings were significant predictors of IDH-wt instead of IDH-mut: thalamus invasion, contralateral cerebral hemisphere invasion, location adjacent to the ventricular walls, higher FA value, and lower MD value. The T/N ratio for all tracers was significantly higher for IDH-wt than for IDH-mut. In a composite diagnosis based on nine parameters, including age, 84.4% of cases with 0–4 points were of IDH-mut; conversely, 100% of cases with 6–9 points were of IDH-wt. Composite diagnosis using all parameters, including MRI and PET findings with significant differences, may help guide treatment decisions for early-stage gliomas. [ABSTRACT FROM AUTHOR]